No Data
No Data
Neurogene's Promising Clinical Progress and Financial Stability Earns Buy Rating
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $50
Baird Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $38
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Analyst Ratings